pharmaphorum3d
A history of Novartis
Novartis is one of the world's top pharmaceutical companies ... In 1970, Ciba and Geigy merged to form Ciba-Geigy Ltd. Ten years later, a biotechnology unit was established.
STAT12d
Novartis raises profit guidance, pushes off myelofibrosis drug submission
LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...
FiercePharma5d
In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals
As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...
BioSpace4d
Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells
A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech ...
Investopedia11d
Novartis Posts Results Above Estimates, Raises Outlook
The Swiss pharmaceutical firm now forecasts 2024 core operating income growth of a high-teens percentage, compared with its previous target of a mid- to high-teens percentage. Novartis now ...
Novartis11d
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
'Pure-play' Novartis Raises 2024 Financial Targets
Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...
Wall Street Journal11d
Novartis Lifts Guidance Again After Key Drugs Help Results
Novartis NOVN-1.67%decrease ... boosted by revenue from its blockbuster drugs. The Swiss pharmaceutical giant said Tuesday that it now expects its core operating profit—one of its preferred ...
Pharmaceutical Technology on MSN4d
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA
The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...
India Infoline2d
Torrent Pharmaceuticals Ltd Company Summary
Torrent Pharmaceuticals Limited, the flagship Company of the ... The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization ...
PMLiVE9d
Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML
Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a new subset of chronic myeloid leukaemia (CML) patients. The STAMP inhibitor ...